GlassScriptPhysician profile
Melissa Fowler
NPI 1629334271
$7,372.80
in general payments reported to CMS, 2019-2025
27 companies · $2,510 in 2025
The $2,510 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,674 · 2024: $3,188 · 2025: $2,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,372.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,403.31 | 2023-2025 | |
| Ucb, INC. | $1,344.63 | 2023-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,290.43 | 2023-2025 | Enbrel, Otezla, Krystexxa |
| Pfizer INC. | $480.60 | 2023-2025 | |
| Organon LLC | $383.97 | 2023-2025 | Hadlima, Renflexis |
| Astrazeneca Pharmaceuticals LP | $324.63 | 2023-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.39 | 2023-2025 | Ofev, Cyltezo |
| Radius Health, INC. | $279.90 | 2023-2025 | Tymlos |
| Genzyme Corporation | $263.71 | 2023-2025 | |
| Lilly USA, LLC | $241.50 | 2023-2024 | Taltz |
| Janssen Biotech, INC. | $221.66 | 2023-2025 | Tremfya, Simponi Aria |
| Octapharma USA, INC. | $137.69 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Mallinckrodt Hospital Products INC. | $121.14 | 2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $95.74 | 2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $72.11 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $70.99 | 2023 | Gelsyn-3 |
| Sobi, INC | $58.86 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $50.02 | 2024 | Strensiq |
| Sandoz INC. | $45.07 | 2024 | Hyrimoz |
| Teva Pharmaceuticals USA, INC. | $31.99 | 2023-2024 | Truxima |
| Kiniksa Pharmaceuticals, LTD. | $31.17 | 2023 | Arcalyst |
| Glaxosmithkline, LLC. | $29.50 | 2024-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $27.92 | 2025 | |
| Mylan Institutional INC. | $23.36 | 2023 | Hulio |
| Celltrion USA INC. | $16.51 | 2024 | Vegzelma |
| Kiniksa Pharmaceuticals International, Plc | $13.53 | 2024 | Arcalyst |
| Ani Pharmaceuticals, INC. | $13.47 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.